Articles tagged with Chemotherapy
A research team led by Dr. Velusamy Rangasamy and Dr. Ajay Rana has identified a key protein that can serve as a target for estrogen-receptor positive breast cancer treatment. This finding could lead to the development of more targeted therapies to improve chemotherapy effectiveness.
Scientists created oil droplets that can solve complex mazes using pH gradients, potentially helping cancer drugs reach tumors and nano-machines move accurately. This technology could be used to design new anti-cancer drugs and improve the navigation of futuristic nano-machines.
A new multi-targeted treatment regimen combining chemotherapy and targeted drugs improves progression-free survival and tumour response in patients with metastatic renal-cell carcinoma. The study found a clinical benefit rate of over 90% with manageable side effects.
Researchers found that Herceptin significantly improved event-free survival in patients with HER2-positive locally advanced or inflammatory breast cancer, with a 3-year event-free survival rate of 71% compared to 56%. The treatment was well-tolerated, with only two patients experiencing symptomatic cardiac failure.
A combined chemotherapy regimen of capecitabine and oxaliplatin given before chemoradiotherapy and surgery is well tolerated and shows promising anti-tumour activity in patients with poor-risk rectal cancer. The treatment improves overall survival rates, with 68% of patients progression-free after 3 years.
Evolutionary theory is being applied to various medical questions, from aging and mental illnesses to cancer and antibiotic resistance. Future physicians may face tests on evolution, with increased emphasis on incorporating evolutionary concepts into medical practice.
Phase II study results of ASA404 showed improved overall survival in patients with squamous and non-squamous NSCLC compared to chemotherapy alone. The drug's unique mechanism of action inhibits tumor blood flow, providing a potential new treatment option for limited options.
A new 21-gene test is helping doctors and patients make informed treatment decisions by predicting whether chemotherapy is necessary for early-stage breast cancer. The test, which examines tumor gene activity, has led to changes in treatment recommendations in 31.5% of cases, with most changes favoring avoidance of chemotherapy.
A U-M study reveals that a specific receptor, CXCR1, triggers growth of breast cancer stem cells in response to inflammation and tissue damage. Researchers found that blocking this receptor using an existing anti-inflammatory drug repertaxin kills breast cancer stem cells and prevents metastasis in mice.
Researchers have found that figitumumab has antitumor activity in Ewing's sarcoma, a cancer commonly affecting male teenagers. The drug targets the insulin-like growth factor signalling pathway, and initial studies have shown safety and efficacy in patients with refractory Ewing's sarcoma.
Researchers at UCLA's Jonsson Comprehensive Cancer Center discovered that deoxycytidine kinase (dCK) enzyme plays a crucial role in the development of healthy immune systems. Mice without this enzyme have defects in their adaptive immune system, producing very low levels of T and B lymphocytes.
Patients with NSCLC and EGFR mutations showed significantly improved progression-free survival with gefitinib treatment. Gefitinib was also better tolerated than chemotherapy, with fewer severe adverse events.
Researchers developed an animal model showing four commonly used chemotherapy drugs disrupt new brain cell birth and that IGF-1 may partially reverse the condition. The study is relevant to cancer survivors experiencing cognitive decline after chemotherapy.
A group of heart drugs, cardiac glycosides, have been found to be effective against human colon cancer cells, with varying degrees of sensitivity. The findings suggest that these heart drugs could potentially improve colon cancer outcomes when used alone or in combination with conventional chemotherapy.
Using Herceptin with chemotherapy reduces the risk of cancer recurrence by 25% compared to using it after chemotherapy. This new standard of care may benefit up to 10,000 women worldwide each year.
A phase 3 trial found that adding chemotherapy to tamoxifen treatment significantly improves disease-free survival in postmenopausal women with node-positive breast cancer. The benefit is maximized when tamoxifen follows chemotherapy.
A landmark study confirms that chemotherapy with tamoxifen improves survival rates for postmenopausal women with estrogen receptor-positive breast cancer. A second study identifies a subset of patients who may not benefit from chemotherapy despite being at higher risk, suggesting a potential need to reassess treatment guidelines.
A landmark study by Dr. Kathy Albain of Loyola University Health System found that chemotherapy improves survival in postmenopausal breast cancer patients, while a multigene test can identify those who may not benefit from chemotherapy. The study established the standard of care for tamoxifen treatment in relation to chemotherapy.
Researchers at Dana-Farber Cancer Institute found that midostaurin, a kinase inhibitor targeting FLT3 cell receptor, combined with chemotherapy reduced circulating leukemia cells in AML patients. Complete responses occurred in 80% of patients with mutated FLT3, and high survival rates were observed one and two years after treatment.
Researchers analyzed CT scans of 50 surgical patients with metastatic colorectal cancer to predict overall survival. The findings showed that morphologic changes on CT images correlated with pathologic response and improved survival.
A study found that morphologic changes on CT scans after bevacizumab-containing chemotherapy can predict overall survival in patients with stage IV colorectal cancer. The changes, including tumor size reduction and unique structural alterations, were strongly correlated with pathologic response and improved survival.
A new study found that long-term testicular cancer survivors who received cisplatin-based chemotherapy experienced more severe neurological side effects compared to those not treated with chemotherapy. The study suggests that dose-intensive chemotherapy regimens can limit ototoxicity and hearing impairment in these patients.
A phase 2 trial investigates the effectiveness of a combined chemotherapy regimen of gemcitabine and oxaliplatin (GEMOX-B) plus bevacizumab in treating advanced biliary-tract cancers, showing an overall response rate of 40% and stable disease in 29%. Whole-body PET scans show promising results for monitoring treatment response.
The editorial highlights exaggerated fears and hopes in media coverage of cancer research, such as uncontrolled study results and unwarranted fear from studies. Journalists can alleviate this problem by asking the right questions, highlighting study limitations, and providing data to support claims.
Researchers have developed a new mouse variety that approximates human genetic diversity, allowing for more accurate testing of chemotherapeutic drugs. The study aims to reduce the risk of adverse reactions and improve treatment outcomes for cancer patients.
A recent study found that adding capecitabine to a standard chemotherapy regimen for breast cancer improves recurrence-free survival, but at the cost of increased adverse events. The treatment was associated with more cases of diarrhea and hand-foot syndrome, while also causing more severe neutropenia.
Scientists at Michigan State University are using a $3 million NIH grant to study the synthesis of medicinal compounds in popular plants. The goal is to understand how genes contribute to this process, leading to cheaper and more effective drug development.
A review of nearly 150 papers found that tinnitus causes significant distress, with many patients told nothing can be done to alleviate symptoms. The researchers advocate for increased support, guidance, and treatment options for those affected.
Researchers at Duke University have developed a simple and inexpensive method for loading cancer drugs into nano-scale delivery vehicles. The new formulation showed promising results in animal models, eliminating tumors after a single treatment while reducing side effects associated with systematic chemotherapy.
Researchers are developing innovative treatments to starve cancer cells of glucose, a strategy that has shown promising results in breast and colon cancer cases. RNA interference is also being explored as a gene therapy approach to block genes involved in cancer growth, with significant progress made in administering these medicines.
Combining chemotherapy with radiotherapy more than doubles event-free survival for patients with locally advanced head and neck cancer without prior surgery. Non-platinum-based chemotherapy shows long-term benefit with lower toxicity compared to platinum therapies.
Researchers found that leukemia cells reliant on MCL-1 are more sensitive to chemotherapeutic drugs than those dependent on BCL-2. A block in apoptosis selected during oncogenesis can significantly impact cancer's response to chemotherapy.
A team of University of Alberta researchers successfully synthesized a natural substance called Palmerolide A, which shows exceptional potential to specifically treat melanoma. The potency of palmerolide is exceptional and may prove to be more effective with less toxicity than current chemotherapy approaches.
Research reveals that up to a quarter of testicular cancer survivors experience long-term neurological, hearing, and circulation problems, as well as a higher risk of secondary cancers. However, many survivors can successfully father children after treatment, with up to 80% successful pregnancies.
Researchers found that a multivariable prediction model can accurately identify patients at low risk of recurrence, allowing for reduced chemotherapy treatments without compromising patient outcomes. The study suggests personalized medicine approach could improve cancer treatment decisions.
A phase 2 study found that adding imatinib mesylate to regular chemotherapy increased three-year survival rates for children with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) from 30-35% to 87%. The drug was well-tolerated and showed no significant side effects.
Researchers at Northwestern University discovered a potent new chemotherapy cocktail that inhibits breast cancer cell invasion by half. The mix of dasatinib and doxorubicin targets the Src kinase enzyme, believed to play a key role in breast cancer metastasis.
A new approach to treating malignant brain tumors has been discovered, with chemotherapy alone proven to be just as effective as traditional radiation therapy. The study identified a key gene mutation called IDH1 that predicts a better prognosis for patients, regardless of treatment.
Masitinib targets mast cells and shows greater activity and selectivity against KIT than benchmark TKI imatinib. The study demonstrates masitinib's potential in treating KIT and PDGFR-dependent diseases, including various cancers, inflammatory diseases, and neurological indications.
A new study found that investing in colorectal cancer screening programs could reduce treatment costs by more than half. The study suggests that the increasing use of expensive cancer drugs will make screening programs more cost-effective, making them a desirable investment for governments and insurance companies.
Researchers discover a drug that inhibits TAK-1 enzyme, making pancreatic cancer cells sensitive to chemotherapy. The combination of the drug with classic anti-cancer drugs shows significant tumor reduction and increased survival rates in mice.
A phase I extension study has shown that 64% of patients with the BRAF mutation experienced partial response to a new compound, with rapid and dramatic shrinking of metastatic tumours. The treatment has fewer side effects compared to standard chemotherapy and is being explored as part of larger trials.
A Purdue University researcher developed a fiber-optic sensor capable of measuring oxygen intake rates in real-time. The self-referencing optrode has broad applications across disciplines, including biomedical science, agriculture, and material science.
A new study found that targeted heat therapy significantly improves overall survival and reduces cancer recurrence in patients with locally advanced soft tissue sarcomas. The treatment, which involves heating the tumor to kill cancer cells, also makes chemotherapy more effective and improves blood flow.
New research finds that adding cetuximab to chemotherapy reduces the risk of death from advanced non-small cell lung cancer by 13%, while also slowing disease progression and increasing the chance of tumor shrinkage. The study, which included over 2,000 patients, also found a 10% improvement in progression-free survival.
A phase III randomised controlled trial found that dose-dense weekly paclitaxel plus carboplatin improved survival in women with advanced epithelial ovarian cancer, with a median progression-free survival of 28 months compared to 17 months. Overall survival at 3 years was also higher in the dose-dense regimen group.
A randomized phase III study found that pemetrexed significantly improved progression-free survival (4.3 months vs 2.6 months) and overall survival (13.4 months vs 10.6 months) compared to placebo in patients with advanced non-squamous NSCLC who did not progress after initial platinum-based chemotherapy.
A new once-daily medication has shown to be as effective as multiple dosings for treating the most common mouth infection in HIV/AIDS patients. The treatment, a small tablet applied daily, provides relief from oral candidiasis (OC) with few or no side effects.
A new treatment protocol using dexamethasone instead of prednisone and less intensive chemotherapy showed similar event-free survival in non-high risk patients but better results in high-risk patients, reducing the risk of side effects. Overall, the treatment strategy improved survival rates for children with acute lymphoblastic leukemia.
American mayapple, a common weed in US, contains high podophyllotoxin levels, offering potential for commercial production of anti-cancer compound. Researchers identify eastern US colonies with high podophyllotoxin content, paving the way for development of high-value crop.
A Phase II study shows Avastin significantly increases response rates, progression-free survival times and survival rates in patients with recurrent glioblastoma. The treatment was found to be effective both alone and in combination with chemotherapy, improving patient outcomes and quality of life.
A new tumor marker has been identified for brain tumor resistance, allowing for targeted therapy approaches. The discovery of a
A study found that chemotherapy impairs sleep-wake activity rhythms in breast cancer patients, leading to shorter days and disrupted biological clocks. The disruption worsens with repeated chemotherapy cycles, highlighting the need for routine screening and management of sleep disturbances.
Researchers at University of Utah Health have made a surprising connection between high levels of GSTM4 protein and poor chemotherapy response in Ewing's sarcoma patients. The study suggests that targeting GSTM4 could lead to more effective treatments for individual patients.
Researchers found that nadroparin almost halves the risk of developing blood clots in ambulatory cancer patients receiving chemotherapy. The study, published in The Lancet Oncology, showed a significant reduction in thromboembolic events in patients treated with nadroparin compared to those receiving placebo.
Researchers found that a key protein called Fbx6 helps eliminate activated Chk1, but defects in this process can lead to chemotherapy resistance. By understanding how cancer cells respond to Chk1 degradation, scientists may develop new treatments with fewer side effects.
A research team led by Professor Patrick Gunning at the University of Toronto has developed molecules that inhibit Stat3, a protein involved in almost all cancers. These inhibitors show selectivity against cancer cells but not healthy cells, offering potential for improved chemotherapy efficacy and reduced side effects.
Scientists at Dana-Farber Cancer Institute have discovered the mechanism behind a DNA repair-blocking approach to cancer treatment, suggesting that these drugs can sensitize cancer cells to chemotherapy. The findings also indicate that normal cells may be protected from DNA damage by these inhibitors.
New research by MIT cancer biologists shows that tumor mutations can predict chemotherapy success. Genetic profiling of tumors can help doctors tailor treatments to each patient. The study identified specific genes and their interactions to determine how well cancer cells respond to chemotherapy.
New commentary published in JNCI Journal of the National Cancer Institute discusses treatment options for metastatic breast cancer. The European School of Oncology Metastatic Breast Cancer Task Force recommends sequential chemotherapy with a single agent for patients without rapid progression or life-threatening metastasis.